Daniel L Kisner
CIK 1073407 · last filed 2026-02-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CALPW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CARLSBAD, CA 92008
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 1,500 | $15.50 | $23.2K | $10.8K | 20 | 2026-02-10 |
| Oncternal Therapeutics, Inc. (ONCT) Delisted | Director | 500 | $0.53 | $263 | $23.8K | 9 | 2024-06-24 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Director | 47,824 | $1.30 | $62.2K | -$80 | 10 | 2023-10-11 |
| Histogen Inc. (HSTO) Delisted | Director | — | $0.21 | — | $0 | 4 | 2023-06-21 |
| Histogen Inc. (CNAT) Delisted | Director | 714 | — | — | $23.0K | 10 | 2019-07-01 |
| Apollo Endosurgery, Inc. (LPTN) Delisted | Director | — | — | — | $0 | 4 | 2016-02-18 |
| CALIPER LIFE SCIENCES INC (CALPW) Delisted | Director | 109,301 | — | — | -$272.7K | 10 | 2008-06-05 |
Recent Filings · Page 5 of 7
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-10-14 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-08-06 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-15 | Histogen Inc. (CNAT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-28 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-04-10 | Histogen Inc. (CNAT) Delisted | Buy (P) | +4,000 | $23.0K | EDGAR |
| 2015-02-12 | Apollo Endosurgery, Inc. (LPTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-02-25 | Histogen Inc. (CNAT) Delisted | Other (J) | +3,145 | $0 | EDGAR |
| 2014-02-12 | Apollo Endosurgery, Inc. (LPTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-02-11 | Histogen Inc. (CNAT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-10-30 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Buy (P) | +10,000 | $10.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.